South San Francisco -based Harpoon Therapeutics has raised about $76m in an initial public offering, amid a biotech boom that shows no sign of slowing. The company offered 5.4 million shares at $ 14 per share, with trading launching on Immunotherapy on Last month . Nasdaq firm Harpoon focuses on the development of drugs called T cell engagers, which engage a patient's T cells to locate and kill cancer cells. Its lead treatment, Harpoon Therapeutics , is currently in a phase one trial for patients with advanced prostate cancer.
San Francisco-based Harpoon Therapeutics has raised about $76m in an initial public offering, amid a biotech boom that shows no sign of slowing. The company offered 5.4 million shares at $14 per share, with trading launching on Nasdaq on Friday 8 February. Immunotherapy firm Harpoon focuses on the development of drugs called T cell engagers, which engage a patient's T cells to locate and kill cancer cells. Its lead treatment, HPN424, is currently in a phase one trial for patients with advanced prostate cancer.